BPC-157: Gastric Pentadecapeptide Research

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, derived from a region of the BPC (Body Protection Compound) protein isolated from human gastric juice. With a molecular weight of 1,419.5 Da and a confirmed purity standard of ≥99% by RP-HPLC in research-grade preparations, it has become one of the most widely used reference peptides in preclinical in-vitro and in-vivo research over the past three decades.

Sequence and Synthesis

The 15-amino acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is a partial sequence of human gastric juice BPC protein. It is entirely synthetic — not extracted from biological tissue — which allows for batch-to-batch consistency and defined purity specifications not achievable with tissue-derived isolates. Identity is typically confirmed by ESI-MS with an observed mass matching the calculated 1,419.6 Da within instrument tolerance.

BPC-157 is stable as a lyophilized powder, resistant to acid degradation (consistent with its gastric origin), and is typically reconstituted in sterile saline or bacteriostatic water for in-vitro assay use.

Angiogenesis Research Models

The most extensively documented in-vitro application of BPC-157 involves angiogenesis assays. Endothelial cell tube formation assays (Matrigel-based), scratch wound migration assays, and VEGF-pathway gene expression studies have all used BPC-157 as a reference compound. The Sikirić research group at the University of Zagreb has published the majority of this preclinical work, examining BPC-157's effects on VEGFR2/Akt/eNOS signaling cascades in endothelial cell models.

In tube formation assays, BPC-157 is typically applied at concentrations in the microgram-per-milliliter range to examine whether it modulates endothelial sprouting and network formation compared to vehicle-treated controls. These experiments are conducted in cell culture and do not constitute evidence of clinical efficacy.

Fibroblast and Connective Tissue Models

Beyond angiogenesis research, BPC-157 has been used in fibroblast cell culture systems to examine its interactions with growth factor signaling. Studies have looked at its effects on fibroblast proliferation rate, migration in scratch assays, and expression of collagen-type-I, fibronectin, and FAK (focal adhesion kinase) — the latter relevant to cell-matrix adhesion research.

The peptide has also appeared in co-culture models examining paracrine interactions between endothelial cells and fibroblasts, serving as a tool to probe how exogenous peptides affect intercellular communication in tissue-model systems.

Gastrointestinal Mucosal Research

Given its gastric origin, BPC-157 has been applied in in-vitro gastrointestinal epithelial models. Gastric and intestinal epithelial cell lines (e.g., AGS, Caco-2) have been used to examine BPC-157's effect on tight-junction protein expression, transepithelial electrical resistance (TEER), and epithelial restitution after mechanical disruption. These are fundamentally basic-science assays examining peptide-epithelium interactions.

Research Considerations

BPC-157 supplied by DRAGNZ PEPS is lyophilized to 10 mg per vial with identity confirmed by ESI-MS (observed: 1,419.6 Da) and purity ≥99% by RP-HPLC. As with any research peptide, reconstituted solutions should be prepared fresh or stored as working aliquots at −20°C and avoided repeated freeze-thaw cycles to maintain assay consistency.